Google
Trusted Resources: News & Events
Latest announcements and gatherings
CTX001 Earns FDA’s Fast Track Status for Treating Sickle Cell Disease
The U.S. Food and Drug Administration (FDA) has awarded fast track status to investigational therapy CTX001 to treat sickle cell disease.
A Phase 1/2 clinical trial (NCT03745287) is recruiting patients.
CTX001 uses the CRISPR gene-editing technology to increase the production of fetal hemoglobin in patients’ red blood cells.
Fetal hemoglobin is a form of hemoglobin that naturally exists when one is born and later is replaced by the adult form of hemoglobin.
For the treatment, doctors collect a patient’s own hematopoietic stem cells (cells from the bone marrow) and modify them in the laboratory so they can produce high levels of fetal hemoglobin.
+myBinderRelated Content
-
Sickle Cell Anemia Explanationhttps://www.youtube.com/watch?v=3ar56G4N...
-
GBT announces positive top-line data from part A of the phase 3 HOPE study of Voxelotor in sickle cell diseaseGlobal Blood Therapeutics, Inc. today an...
-
World’s Largest Sickle Cell Disease Stem Cell Library UnderwayScientists in Boston are creating a stem...
-
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell diseaseAs defined by the American Physical Ther...
-
Crizanlizumab 5.0 mg/kg increased the time to first on-treatment sickle cell pain crisis: a subgroup analysis of the...In the 52-week SUSTAIN study, which comp...
-
Safety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
-
A new Sickle Cell Disease Drug Holds Much Promise but Most Sufferers Won’t be Able to Afford itThe regulatory approval of a groundbreak...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.